This is a working overview of anti-doping category, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-02 and is reviewed periodically as new material appears.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Autoantibodies are usually absent or very low, so instead of being given in standard reference ranges, the values usually denote where they are said to be present, or whether the test is a positive test. There may also be an equivocal interval, where it is uncertain whether there is a significantly increased level.
Unlike most tubers, but in common with many other members of the Asteraceae (including the artichoke), Jerusalem artichoke tubers store their carbohydrates as the polysaccharide inulin (not to be confused with the peptide insulin) rather than as starch. This has made them an important source of inulin used as a dietary fiber in food manufacturing. Jerusalem artichoke can propagate with seeds and tubers but the use of tubers leads to higher yields. For planting, the tubers are cut into pieces with three to five buds that are placed in 5–10 centimetres (2–4 in) depth in the soil. Jerusalem artichoke has low nutrient requirements and needs less nitrogen than other energy crops. The competitiveness against weeds is high, making weed control easier but also making it harder to grow a different culture afterward, since some small tubers usually remain in the ground after harvest. The plant's high competitiveness may be due to allelopathic effects, high plant size, and rapid growth rate. Crop yields are high, typically 16–20 tonnes per hectare (7–9 short ton/acre) for tubers, and 18–28 tonnes per hectare (8–12 short ton/acre) green weight for foliage. Tubers remaining in the ground lie dormant over winter and can handle temperatures as low as −30 °C (−22 °F). Jerusalem artichoke also has potential for production of ethanol fuel, using inulin-adapted strains of yeast for fermentation. The tubers are used for cooking and baking in the same ways as potatoes, but unlike the potato, they can also be eaten raw.
=== Reston virus: monkeys with ebola virus brought to U.S. === In December 1989, several crab-eating macaques with the Zaire ebolavirus were imported from Mindanao in the Philippines to the company's facility in Reston, Virginia. The strain of the virus became known as the Reston virus. It was the first ebola virus that emerged outside of Africa and was also the first known natural infection of ebola virus in nonhuman primates. The facility was abandoned and torn down and the variant turned out to be non-lethal to humans. The incident was an inspiration for The Hot Zone, a book by Richard Preston published in 1994. In March 1996, two macaques that had been shipped to the company's facility in Alice, Texas, tested positive for the Ebola virus from a group of 100 obtained from the same supplier. The virus strain was the same non-lethal Reston virus as in the earlier incident.
== Challenges and future outlook == The commercial viability of Pakistan’s oil potential remains uncertain, constrained by geopolitical volatility, investor hesitation, and logistical hurdles. Governance remains a concern—including equitable integration of provincial stakeholders and transparency in licensing. There is anticipation for the first shipment of U.S. crude oil to Pakistan, likely in October 2025 via Cnergyico and Vitol, symbolizing the deal's early implementation. The potential of exports to India remains speculative, heavily contingent on regional diplomacy and stability.
Sources: en.wikipedia.org
== List legend == Each group of radionuclides, starting with the longest-lived primordial radionuclides, is sorted by decreasing half-life, but the tables are sortable by other columns. All columns sort by usual lexicographical order; in the case of the nuclide column this gives order on the mass number A.
==== Natural gas ==== Commonly, HIC of natural gas from the same well has a trend of δDmethane < δDethane < δDpropane < δDC4+. This is because most natural gas is thought to be generated by stepwise thermal cracking that is mostly irreversible and thus governed by normal kinetic isotope effects (KIE) that favor light isotopes. The same trend, known as "the normal order", holds for carbon isotopes in natural gas. For example, Angola gas reportedly has a methane δD range of −190‰ to −140‰, an ethane δD of −146‰ to −107‰, a propane δD of −116‰ to −90‰, and a butane δD of −118‰ to −85‰. However, some recent studies show that opposite patterns could also exist, meaning δDmethane > δDethane > δDpropane. This phenomenon is often called 'isotopic reversal' or 'isotopic rollover'. The isotopic order could also be partly reversed, like δDmethane > δDethane < δDpropane or δDmethane < δDethane > δDpropane. Burruss et al. found that in the deepest samples of northern Appalachian basin the hydrogen isotopic order for methane and ethane is reversed. Liu et al., also found partial reversal in oil-related gas from the Tarim Basin. The mechanism causing this reversal is still unknown. Possible explanations include mixing between gases of different maturities and sources, oxidation of methane, etc. Jon Telling et al., synthesized isotopically reversed (in both C and H) low-molecular alkanes using gas-phase radical recombination reactions in electrical discharge experiments, providing another possible mechanism. Methane is the main component of natural gas.
Two pathways for PLP are currently known: one requires deoxyxylulose 5-phosphate (DXP), while the other does not, hence they are known as DXP-dependent and DXP-independent. These pathways have been studied extensively in Escherichia coli and Bacillus subtilis, respectively. Despite the disparity in the starting compounds and the different number of steps required, the two pathways possess many commonalities. The DXP-dependent pathway:
Polyhistidine tags most commonly consist of six histidine residues. Tags with up to twelve histidine residues or dual tags attached via short linker are not uncommon though and may improve purification results by enhancing binding to the affinity resin, allowing for increased stringency of washing and separation from endogenous proteins. The tag can be added to a gene of interest using methods common to most purification tags. The most basic method is to subclone the gene of interest into a vector containing a polyhistidine tag sequence. Many vectors for use with various expression systems are available with polyhistidine tags in a variety of positions and with differing protease cleavage sites, other tags etc. However, if an appropriate vector is unavailable or the tag needs to be inserted at a location other than the proteins N- or C-terminus, the gene of interest can be either directly synthesised containing a polyhistidine tag sequence or various methods based on PCR can be used to add the tag to a gene. A common approach is to add the coding sequence for the polyhistidine tag to the PCR primers as an overhang.
== Classification and uses == Moisture may be present as adsorbed moisture at internal surfaces and as capillary condensed water in small pores. At low relative humidities, moisture consists mainly of adsorbed water. At higher relative humidities, liquid water becomes more and more important, depending or not depending on the pore size can also be an influence of volume. In wood-based materials, however, almost all water is adsorbed at humidities below 98% RH. In biological applications there can also be a distinction between physisorbed water and "free" water — the physisorbed water being that closely associated with and relatively difficult to remove from a biological material. The method used to determine water content may affect whether water present in this form is accounted for. For a better indication of "free" and "bound" water, the water activity of a material should be considered. Water molecules may also be present in materials closely associated with individual molecules, as "water of crystallization", or as water molecules which are static components of protein structure.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.